These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10505300)

  • 21. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.
    von Keutz E; Schlüter G
    Am J Cardiol; 1998 Aug; 82(4B):11J-17J. PubMed ID: 9737641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
    Mück W; Park S; Jäger W; Voith B; Wandel E; Galle PR; Schwarting A
    Int J Clin Pharmacol Ther; 2001 May; 39(5):192-8. PubMed ID: 11380064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study.
    Hanefeld M; Deslypere JP; Ose L; Durrington PN; Farnier M; Schmage N
    J Int Med Res; 1999; 27(3):115-29. PubMed ID: 10505301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
    Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
    Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.
    Mück W
    Drugs; 1998; 56 Suppl 1():15-23; discussion 33. PubMed ID: 9740537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical and clinical pharmacology of cerivastatin.
    Bischoff H; Heller AH
    Am J Cardiol; 1998 Aug; 82(4B):18J-25J. PubMed ID: 9737642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single administration of cerivastatin, an HMG-CoA reductase inhibitor, improves the coronary flow velocity reserve: a transthoracic Doppler echocardiography study.
    Takagi A; Tsurumi Y; Ishizuka N; Omori H; Arai K; Hagiwara N; Kasanuki H
    Heart Vessels; 2006 Sep; 21(5):298-301. PubMed ID: 17151817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.
    Renders L; Czock D; Schöcklmann H; Kunzendorf U
    Int J Clin Pharmacol Ther; 2003 Nov; 41(11):499-503. PubMed ID: 14620947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man.
    Sachse R; Ochmann K; Rohde G; Mück W
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):517-20. PubMed ID: 9799053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.
    Mantel-Teeuwisse AK; Klungel OH; Egberts TC; Verschuren WM; Porsius AJ; de Boer A
    Drug Saf; 2004; 27(1):63-70. PubMed ID: 14720086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
    Scharnagl H; Stojakovic T; Winkler K; Rosinger S; März W; Boehm BO
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):372-5. PubMed ID: 17701882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerivastatin.
    Cheng-Lai A
    Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacy clinics. Medication of the month. Cerivastatin (Lipobay, Cholstat)].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):117-20. PubMed ID: 10769583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].
    Zeitlinger M; Müller M
    Wien Med Wochenschr; 2003; 153(11-12):250-4. PubMed ID: 12879633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controversy surrounding the safety of cerivastatin.
    Davidson MH
    Expert Opin Drug Saf; 2002 Sep; 1(3):207-12. PubMed ID: 12904136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhabdomyolysis and cerivastatin: was it a problem of dose?
    Kalaria D; Wassenaar W
    CMAJ; 2002 Oct; 167(7):737. PubMed ID: 12389822
    [No Abstract]   [Full Text] [Related]  

  • 38. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.
    Omori H; Nagashima H; Tsurumi Y; Takagi A; Ishizuka N; Hagiwara N; Kawana M; Kasanuki H
    Br J Clin Pharmacol; 2002 Oct; 54(4):395-9. PubMed ID: 12392587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
    Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
    Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.
    Lau TK; Leachman DR; Lufschanowski R
    Tex Heart Inst J; 2001; 28(2):142-5. PubMed ID: 11453128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.